Table 1. Ongoing trials for colon, rectal and appendiceal cancers.

Trial phase	Cancer type	Treatment arm	Control arm	Sponsor/country	Primary outcome	ECD
III	Appendiceal and colorectal	CyRS + NIPEC	CyrS + HIPEC	University of Ghent, Belgium	Morbidity and mortality	2015
II	Colorectal	FOLFOX + cetuximab + CyRS + HIPEC + FOLFOX	N/A	University of Regensburg, Germany	PFS	2015
II	Appendiceal	CyRS + HIPEC With oxaliplatin or mitomycin-C	N/A	Wake Forest University, USA	Treatment-related toxicities	2016
I/II	Colorectal	CyRS + HIPEC + MOC31PE immunotoxin	N/A	Oslo University Hospital, Norway	Adverse events and tolerability	2016
III	Colorectal*	Surgery + AC + HIPEC	Surgery + AC	Gustave Roussy, France	DFS	2016
I/II	Colorectal	CyRS+ HIPEC + intraperitoneal EGEN-001**	N/A	EGEN, Inc., USA	PFS, OS, and tumor growth assessment	2017
III	Colorectal*	Surgery + HIPEC	Surgery	Zhejiang University, China	DFS	2017
III	Colorectal*	Surgery + HIPEC	Surgery + AC	Academisch Medisch Centrum-Universiteit van Amsterdam, Netherland	RFSi	2019
II	Appendiceal	CyRS + HIPEC + AC	N/A	University of California in San Diego, USA	PFS	2020

*, high risk for peritoneal carcinomatosis. HIPEC is given to prophylactically; **, novel immunotherapy agent (EGEN-001—interleukin-12 gene in a biocompatible delivery polymer/http://archive.hudsonalpha.org/egen). ECD, estimated completion date; CyRS, cytoreductive surgery; NIPEC, normothermic intraperitoneal chemotherapy; HIPEC, Hyperthermic intraperitoneal chemotherapy; AC, adjuvant chemotherapy; DFS, disease free survival; PFS, progression free survival; OS, overall survival; RFS, recurrence free survival.